Navigation Links
Growing Uptake of Genzyme's Aubagio at Three Months Post-Launch Is Likely Driven by Perceived Product Convenience Even As Neurologists Search to Identify Appropriate Candidates, According to a Recent BioTrends Report
Date:3/6/2013

EXTON, Penn., March 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that 34 percent of surveyed U.S. neurologists have prescribed Genzyme's Aubagio to at least one of their multiple sclerosis (MS) patients at three months post-launch, a significant increase in trial rate from one month post-launch (16 percent). Data from the recently published LaunchTrends®: Aubagio Wave 2 report suggest that expanding Aubagio trial is driven in part by positive perceptions related to the product's convenient once-daily, oral administration. Aubagio, the second oral disease-modifying agent (DMA) to reach the MS market, is the DMA most associated with favorable route of administration/formulation by half of neurologists. Despite the growth in Aubagio prescriber base, Aubagio's current DMA-treated relapsing remitting MS (RRMS) share and average patient volume per prescriber remain low, likely owing to neurologists' continued search to identify appropriate Aubagio candidates, as well as lingering concerns related to hepatotoxicity and teratogenicity. Nevertheless, adoption within individual practices is largely on par with that seen for Novartis's Gilenya, the first oral DMA to reach the MS market, three months after Gilenya's commercial availability*.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

Over the next six months, surveyed neurologists anticipate that Aubagio's DMA-treated RRMS share will increase significantly to over 6 percent, pulling share from Biogen Idec's Avonex, Bayer HealthCare's Betaseron, Teva's Copaxone and Pfizer/EMD Serono's Rebif. In fact, of the two-thirds of neurologists who have never prescribed Aubagio, 69 percent anticipate a trial within the next six months, suggesting Aubagio prescriber base will grow to approximately 80 percent of neurologists by nine months post-launch. High product satisfaction among current prescribers, as well as continued messaging and physician and patient education, will likely contribute to future growth.LaunchTrends: Aubagio is a four-wave syndicated report series that specifically tracks the introduction of Aubagio into the market, based on data collected at one month, three months, six months and one year post-commercial availability of Aubagio from primary research with neurologists. The second wave was fielded January 11-14, 2013 with 73 U.S. neurologists followed by qualitative interviews with a subset of 15 survey respondents. Along with awareness and sources of familiarity, the reports assess neurologists' trial, adoption and usage, including anticipated future trends, of Aubagio within the MS market. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Genzyme's promotional efforts and benchmarking against other previously launched MS agents.

In addition to the LaunchTrends: Aubagio report series, BioTrends will track the U. S. uptake of Aubagio in the biannual TreatmentTrends®: Multiple Sclerosis (US) report series. This syndicated primary research report series provides a view of the broader MS market landscape, including all currently approved DMAs and DMAs in late-stage clinical development.

*Source: LaunchTrends: Gilenya Wave 2, BioTrends Research Group, published February 11, 2011

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders. For more information, contact: BioTrends Research Group Decision Resources GroupEmma Williams

Christopher Comfort610-321-9441

781-993-2597ewilliams@bio-trends.com

ccomfort@dresources.com  


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
2. How the alphabet of data processing is growing: Research team generates flying qubits
3. New Approach to Growing Waste to Value Industry in United States
4. BioSpace Spotlights the growing Midwest Life Science Community
5. Enterologics Highlights Growing News on Probiotics on the Web
6. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
7. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
8. AllCells, LLC Named to Inc. Magazines 500/5000 List of Fastest Growing Companies
9. Breast cancer cells growing in 3D-matrix revert to normal
10. Ramey & Browning Announces New Location and New Hire Firm Is Well Positioned to Address Growing Client Needs In 2013
11. Growing Job-Market Niche Inside The Economic Decline: A Wysebridge Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 18, 2017 , ... Recently recognized by CIO ... announces the migration of its flagship cloud-based product Planet Life Cycle – a ... work management system that merges strategic and financial planning with execution. The solution ...
(Date:7/17/2017)... ... 17, 2017 , ... Neurodevelopmental disorders (NDDs) are clinically and ... features. The advancement of targeted next-generation sequencing (NGS) has been instrumental in accelerating ... , However, designing a custom panel for disease research requires hours of up-front ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS Corporation, a leading worldwide ... its new line of Extreme Environment Shakers today. , Extreme Environment Shakers , ... for optimal cell growth such as cell cultures, solubility studies and extraction procedures. ...
(Date:7/14/2017)... ... July 14, 2017 , ... ... sample preparation of proteins to clean peptides for mass spectrometry (MS) analysis combining ... , The PreOmics iST Kit is based on proprietary technology that contains optimized ...
Breaking Biology Technology:
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):